Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 4/20 | 0.44 |
| ▸ | CCKBR | P32239 | 4/20 | 0.44 |
| ▸ | MMP2 | P08253 | 9/20 | 0.43 |
| ▸ | MMP1 | P03956 | 4/20 | 0.43 |
| ▸ | MMP3 | P08254 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509109 | 0.99 | OPRD1 (0.53) | OPRD1OPRM1OPRK1GRIA1GLP1R | |
| SCHEMBL16509064 | 0.93 | OPRM1 (0.55) | OPRD1OPRM1OPRK1GRIA1 | |
| SCHEMBL16509070 | 0.91 | PTPN1 (0.51) | OPRD1OPRM1OPRK1GRIA1PTPN1 | |
| SCHEMBL16509049 | 0.91 | PTPN1 (0.49) | OPRD1OPRM1OPRK1GRIA1PTPN1 | |
| SCHEMBL13519969 | 0.91 | OPRD1 (0.51) | OPRD1OPRM1OPRK1GRIA1GLP1R | |
| SCHEMBL16509021 | 0.88 | OPRM1 (0.55) | OPRD1OPRM1OPRK1GRIA1GLP1R | |
| SCHEMBL16509082 | 0.88 | OPRM1 (0.55) | OPRD1OPRM1OPRK1GRIA1GLP1R | |
| SCHEMBL16508982 | 0.86 | FAAH (0.41) | OPRD1OPRM1OPRK1PTPN1 | |
| SCHEMBL17176392 | 0.86 | OPRD1 (0.57) | OPRD1OPRM1OPRK1GLP1RCCKAR | |
| SCHEMBL16509050 | 0.86 | OPRM1 (0.51) | OPRD1OPRM1OPRK1GLP1RPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | OPRD1 26/4885OPRM1 31/4885OPRK1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.